GWPH News and Press, GW Pharmaceuticals Plc

The key to investing is “Buy low, sell high”. According to that mantra, periods of weakness are the mother’s milk of future gains. When you see them, you know “this is my chance”. It’s the chance to get involved. This is especially true in industries ...

Today, we revisit biopharma name Zogenix, Inc. for the first time since early this year. Its recently approved compound FINTEPLA continues to ramp up sales and some new approved indications may be on the horizon in the near future. A full investment analysis is presented in the pa...

Alan Brochstein, a friend of the podcast and now a 3peat guest, is the founder of 420 Investor and New Cannabis Ventures. Thoughts on uplisting, the ETF MSOS, volume and valuation issues and confronting the California cannabis landscape. Why there's no winner take all in U.S. cann...

janiecbros/E+ via Getty Images Biotech M&A is poised to heat up again as shares of the SPDR S&P Biotech’s (XBI) have fallen about 25% from their February highs, according to Jefferies. Biotech deals may pick up after a 3-6 month of a large "drawdown" and as prices "normalize" f...

Zhanna Hapanovich/iStock via Getty Images Concerned over high premiums of targets, the large-cap pharmaceutical companies have taken a backseat in acquisitions this year as they focused on repayment of debt accumulated due to previous deals. Meanwhile, with the need to sustain the long-term g...

NetworkNewsWire Editorial Coverage : In May 2013, GW Pharma listed on Nasdaq, selling 3.5 million shares at $8.90 each to investors betting that GW was charting a profitable course as a biotech developing new drugs from cannabis-derived compounds. Legal cannabis was only beginning to gain...

Real Brands Inc (OTCMKTS:RLBD) snuck one under the radar late last week, but investors interested in the CBD and Cannabis space should take note.  The company filed its Form 10 with the SEC. In this case, it was a voluntary filing because the company does report having over $10 million o...

Cannabidiol (CBD) is one of the major cannabinoids found in cannabis; CV Sciences operates in the space via consumer products and drug development. CEO Joseph Dowling on getting CBD out of the hands of the DEA; dialoguing with FDA; leveraging science and data. Strong regulatory en...

Real Brands Inc (OTCMKTS:RLBD) is almost a quarter owned by Turning Point Brands, Inc. (NYSE:TPB), which is a third owned by a multi-billion dollar hedge fund with a vested interest in helping TPB, and its major interests and partners, secure necessary financing on strong investor-friendly te...

Zhanna Hapanovich/iStock via Getty Images Jazz Pharmaceuticals (JAZZ) estimates ~18.1% of additional revenue in 2021 as a result of the acquisition of GW Pharmaceuticals (GWPH), the updated financial guidance issued by the company for this year indicates. Including the projected results ...